Crumly & Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $494K | Buy |
7,069
+246
| +4% | +$17.2K | 0.12% | 101 |
|
|
2025
Q1 | $501K | Sell |
6,823
-260
| -4% | -$19.1K | 0.14% | 99 |
|
|
2024
Q4 | $464K | Buy |
7,083
+439
| +7% | +$28.8K | 0.13% | 101 |
|
|
2024
Q3 | $518K | Buy |
6,644
+143
| +2% | +$11.1K | 0.14% | 99 |
|
|
2024
Q2 | $507K | Buy |
6,501
+63
| +1% | +$4.91K | 0.15% | 95 |
|
|
2024
Q1 | $436K | Buy |
6,438
+198
| +3% | +$13.4K | 0.11% | 111 |
|
|
2023
Q4 | $420K | Buy |
6,240
+98
| +2% | +$6.6K | 0.12% | 105 |
|
|
2023
Q3 | $416K | Buy |
6,142
+41
| +0.7% | +$2.78K | 0.16% | 78 |
|
|
2023
Q2 | $437K | Buy |
6,101
+1,147
| +23% | +$82.1K | 0.17% | 79 |
|
|
2023
Q1 | $344K | Sell |
4,954
-8
| -0.2% | -$555 | 0.15% | 86 |
|
|
2022
Q4 | $336K | Buy |
+4,962
| New | +$336K | 0.13% | 74 |
|